Welcome to our dedicated page for Indivior Pharmaceuticals news (Ticker: INDV), a resource for investors and traders seeking the latest updates and insights on Indivior Pharmaceuticals stock.
Indivior Pharmaceuticals, Inc. reports developments in specialty pharmaceuticals for opioid use disorder, with recurring updates centered on SUBLOCADE, its monthly extended-release buprenorphine injection, and evidence supporting medications for opioid use disorder. Company news commonly covers financial results and guidance, commercial performance for SUBLOCADE, scientific and real-world evidence studies, and treatment-use discussions in settings such as correctional facilities.
Indivior updates also include capital-allocation actions, including share repurchase programs and convertible note financing, along with corporate presentations and investor communications tied to the Indivior Action Agenda. The company’s disclosures frame opioid use disorder as a chronic treatable brain disease and emphasize buprenorphine-based prescription treatments.
Indivior (Nasdaq: INDV) intends to offer $400 million aggregate principal amount of convertible senior notes due 2031, with a 30-day option for an additional $60 million. Notes will be senior, unsecured, pay semi-annual interest, and may be converted for cash and/or shares.
Indivior expects to use ~$239 million of net proceeds plus ~$102 million cash to repay its term loan and credit facility, up to ~$75 million to repurchase common stock concurrently, and the remainder for general corporate purposes.
Indivior (NASDAQ: INDV) reported a retrospective real-world study published March 11, 2026 linking 12-month adherence to SUBLOCADE (monthly injectable buprenorphine) with substantially lower healthcare use and costs in commercially insured patients with opioid use disorder.
Key result: SUBLOCADE-adherent patients had $15,017 (42%) lower annual non-MOUD medical costs versus patients adherent to other MOUD ($35,761 vs $50,778), plus the lowest inpatient, ED, and detox utilization. Study limitations include observational claims data and COVID-19 overlap.
Indivior (Nasdaq: INDV) reported Q4 and full‑year 2025 results, including record total SUBLOCADE net revenue of $252M (Q4) and $856M (FY), GAAP net income of $102M (Q4) and $210M (FY), and adjusted EBITDA of $142M (Q4) and $428M (FY). The company entered Phase II of its Action Agenda, launched a nationwide DTC campaign, completed U.S. redomiciliation, paid $295M to resolve a legacy DOJ matter, and authorized a $400M share repurchase program. 2026 guidance: net revenue $1,125M–$1,195M; total SUBLOCADE $905M–$945M; adjusted EBITDA $535M–$575M.
Indivior (Nasdaq: INDV) will participate in two investor conferences in Miami in March 2026. CEO Joe Ciaffoni will host 1x1 and group meetings at Barclays 28th Annual Global Healthcare Conference on March 10, 2026 and at Jefferies Biotech on the Beach Summit on March 11, 2026.
Mr. Ciaffoni will join a public fireside chat on March 10 at 2:00 p.m. U.S. EST; interested investors should contact their Barclays or Jefferies representative to schedule meetings. The fireside chat will be available via webcast.
Indivior (Nasdaq: INDV) will report its fourth quarter and full-year 2025 financial results on Thursday, February 26, 2026 at 7:00 a.m. U.S. EST, followed by a live webcast presentation at 8:00 a.m. U.S. EST led by CEO Joe Ciaffoni and the leadership team.
Webcast access, registration details, and a replay will be available in the Investors section of the company website.
Indivior (Nasdaq: INDV) completed redomiciliation from the United Kingdom to the United States effective Jan 26, 2026. A new Delaware parent, Indivior Pharmaceuticals, Inc. (IPI), is now the parent and Indivior PLC was renamed Indivior Ltd. Shareholders received one IPI common share for each Indivior PLC ordinary share as of the scheme record date, and Indivior common stock remains listed on Nasdaq under INDV. IPI is now a U.S. domestic issuer subject to SEC reporting and Nasdaq exchange rules. The redomiciliation was approved at an extraordinary general meeting on Dec 11, 2025.
Indivior (Nasdaq: INDV) provided full-year 2026 financial guidance and a business update. Management expects total net revenue $1,125M–$1,195M, SUBLOCADE net revenue $905M–$945M, non-GAAP operating expenses $430M–$450M, and adjusted EBITDA $535M–$575M for 2026. The company expects SUBLOCADE net revenue growth of ~11% at the midpoint and a ~35% increase in adjusted EBITDA with a 14 percentage-point expansion in adjusted EBITDA margin at the midpoint.
Recent items: completed Phase I of a restructuring program with expected annual non-GAAP OPEX savings of at least $150M, entered Phase II to accelerate dispense-unit growth, gained inclusion in the S&P SmallCap 600, received shareholder approval to re-domicile to the U.S. effective Jan 26, 2026, and paid $295M to conclude a legacy DOJ matter.
Indivior (Nasdaq: INDV) announced it was added to the S&P SmallCap 600 index, effective December 22, 2025. The company said the inclusion aligns its capital markets presence with a sharpened U.S. business profile and supports growth of SUBLOCADE, its first‑in‑class long‑acting injectable for moderate to severe opioid use disorder.
The S&P SmallCap 600 tracks 600 U.S. small‑cap companies with market capitalizations generally between $1.2 billion and $8.0 billion and applies liquidity and viability criteria for inclusion.
Indivior (Nasdaq: INDV) reported results from a randomized, double-blind trial showing monthly SUBLOCADE extended-release buprenorphine at both 100 mg and 300 mg produced rapid, clinically meaningful reductions in opioid use and improved abstinence in people with moderate-to-severe opioid use disorder.
Participants reduced opioid use from >43 instances/week at screening to 3 instances/week by week 3, a decline maintained through week 38. Post-hoc analyses found the maintenance dose achieved significantly higher abstinence in participants with high-frequency fentanyl use. Both doses were well tolerated with no new safety signals; injection-site reactions were more common with 300 mg but were mild-to-moderate and not linked to discontinuation. The post-hoc findings were exploratory and not pre-specified.
Indivior (Nasdaq: INDV) announced on November 20, 2025 that it has concluded a legacy U.S. Department of Justice matter by paying in full the outstanding obligation of $295 million. With receipt of the payment by the DOJ, the resolution agreement will be terminated.
The company said the payment was funded with cash on hand, and management described the milestone as removing a significant liability and simplifying the company's capital structure while reaffirming its compliance commitments.